GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Curexo Inc (XKRX:060280) » Definitions » EV-to-EBITDA

Curexo (XKRX:060280) EV-to-EBITDA : -72.14 (As of May. 29, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Curexo EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Curexo's enterprise value is ₩368,486 Mil. Curexo's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-5,108 Mil. Therefore, Curexo's EV-to-EBITDA for today is -72.14.

The historical rank and industry rank for Curexo's EV-to-EBITDA or its related term are showing as below:

XKRX:060280' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2071.3   Med: -7.47   Max: 1174.61
Current: -72.14

During the past 13 years, the highest EV-to-EBITDA of Curexo was 1174.61. The lowest was -2071.30. And the median was -7.47.

XKRX:060280's EV-to-EBITDA is ranked worse than
100% of 495 companies
in the Medical Devices & Instruments industry
Industry Median: 15.36 vs XKRX:060280: -72.14

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-29), Curexo's stock price is ₩9470.00. Curexo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-177.000. Therefore, Curexo's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Curexo EV-to-EBITDA Historical Data

The historical data trend for Curexo's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curexo EV-to-EBITDA Chart

Curexo Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 187.59 -433.37 -1,046.82 -264.91 -36.46

Curexo Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.58 -44.99 -27.24 -36.46 -58.71

Competitive Comparison of Curexo's EV-to-EBITDA

For the Medical Devices subindustry, Curexo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curexo's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Curexo's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Curexo's EV-to-EBITDA falls into.


;
;

Curexo EV-to-EBITDA Calculation

Curexo's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=368485.598/-5107.678
=-72.14

Curexo's current Enterprise Value is ₩368,486 Mil.
Curexo's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,108 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curexo  (XKRX:060280) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Curexo's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9470.00/-177.000
=At Loss

Curexo's share price for today is ₩9470.00.
Curexo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-177.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Curexo EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Curexo's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Curexo Business Description

Traded in Other Exchanges
N/A
Address
Pangyo Seven Venture Valley Building, 3 Dong 10th Floor Sampyeong-dong, Seongnam-si, KOR, 463-400
Curexo Inc is a South Korea based company engages in the distribution of medical equipment including Magnetic Resonance Imaging (MRI), endoscopy, and others. It has developed medical devices such as the surgical device for breast cancer and drug delivery technologies.

Curexo Headlines

No Headlines